Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
gptkb:drug |
| gptkbp:approvalYear |
2022
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XX77
|
| gptkbp:brand |
Rezlidhia
|
| gptkbp:CASNumber |
1374639-75-4
|
| gptkbp:chemicalFormula |
https://pubchem.ncbi.nlm.nih.gov/compound/Olutasidenib
|
| gptkbp:developer |
Forma Therapeutics
|
| gptkbp:hasMolecularFormula |
C15H14ClFN4O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
Olutasidenib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
IDH1 inhibitor
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue arthralgia leukocytosis differentiation syndrome |
| gptkbp:target |
gptkb:isocitrate_dehydrogenase_1_(IDH1)
|
| gptkbp:usedFor |
treatment of relapsed or refractory acute myeloid leukemia
|
| gptkbp:bfsParent |
gptkb:Servier_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|